Sanofi Gen­zyme re­treats from its Parkin­son’s deal with gene ther­a­py up­start Voy­ager, part of an $845M pact

Voy­ager $VY­GR plans to launch a piv­otal study of its lead­ing gene ther­a­py for Parkin­son’s dis­ease be­fore the end of the year, but they won …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.